Autoinjectors Market Overview and Introduction

The global autoinjectors market is anticipated to grow at a CAGR of 19.0% from 2019 to 2030.

Autoinjectors or auto-injector is a medical device, which is used to deliver a particular dosage of a drug. These devices are easy-to-handle & cost-effective and can be used by patients, caregivers, and even untrained personnel to deliver drugs of definite dosage. Autoinjectors are used for several applications, namely, rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. These devices offer multiple advantages over its conventional counterparts, namely accuracy, better efficacy, lower probability of needle-stick injuries, consistent dosage delivery, simplicity and safety among others.

The global autoinjectors market is driven by growing popularity of targeted therapies, increasing incidences of anaphylaxis, and rising number of regulatory approvals. Moreover, availability of generic autoinjectors of branded drugs and advent of novel technologies in the segment of drug delivery have been essential in contributing to the extensive growth of the global market. However, presence of alternative dug delivery techniques, namely syringes is likely to restrain the market to a certain extent.

The global autoinjectors market can be segmented into offering, deployment mode, application, end user, and regions.

Autoinjectors Market by Therapy and Type

On the basis of therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. The anaphylaxis is estimated to account for the largest share in the global market. The large share of this segment can be attributed to the increasing prevalence of anaphylaxis worldwide.

On the basis of type, the autoinjectors market can be segmented into disposable autoinjectors, and reusable autoinjectors. In terms of market share, the segment of disposable autoinjectors is estimated to account for the largest market share, owing to ease of use and presence of a built-in glass syringe which makes these devices more convenient among patients with reduced dexterity or visual impairment.

Autoinjectors Market by End Users

Based on the end users, the autoinjectors market is segmented into home care settings, and hospitals & clinics. The Home Care Settings segment is estimated to account for the largest share of the global market. The large share of this segment can be attributed to increasing awareness, rising geriatric population and benefits of using these devices without the guidance of any healthcare professionals among others.

Autoinjectors Market by Region

The global autoinjectors market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW).North America dominated the autoinjectors market, followed by Europe and Asia Pacific. North America will continue to dominate the global autoinjectors market in the forecast period owing to factors such as, increasing incidences of anaphylaxis, growing prevalence of diabetes, rheumatoid arthritis and other ailments, and high disposable income among others. However, Asia Pacific is expected to witness the highest CAGR, with the growth in autoinjectors market centered at China, Korea, Japan and India. Factors such as rising geriatric population, growing economy, increasing awareness and adoption of latest technology in the field of drug delivery systems are driving the growth of the autoinjectors market in this region.

Autoinjectors Market Prominent Players

The prominent players in the global autoinjectors market are Abbvie, Mylan, ELI Lilly, Ypsomed, Amgen, Becton Dickinson and Company, Owen Mumford, Consort Medical, Haselmeier and Shl Group among others.